Tag: Axovant Sciences

March 14, 2019

Axovant Sciences Announces Pricing of $40 Million Public Offering of Common Shares

Axovant Sciences (NASDAQ:AXGT) has announced the pricing of its underwritten public offering of 26.6 million of its common shares at...
December 14, 2018

Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares

Axovant Sciences (Nasdaq:AXON) announced the pricing of its underwritten public offering of 30,000,000 of its common shares at a price...
October 25, 2018

Axovant Doses First Patient in Parkinson’s Trial

The drug, AXO-Lenti-PD, was well tolerated and the patient was able to leave the hospital as expected with no side...
October 25, 2018

Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD

Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, announced dosing of the first patient...
July 9, 2018

Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD

Axovant Sciences (NASDAQ:AXON) today announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from...
June 6, 2018

Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition

Axovant Sciences (NASDAQ:AXON) announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from...